24 Firmen mit Ergebnissen für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ"

Roche Glycart AG

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

Roche Glycart AG

Wagistrasse 10

8952 Schlieren

246 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter Roche Glycart AG

法律声明 - 罗氏集团行为准则

... 法律声 - 罗氏 行为准则 ... 法律声 - 罗氏 行为准则 Navigation Menu 罗氏 行为准则 Roche ZH  汉语 English Français Italiano 日本語 Deutsch ... 法律声 - 罗氏 行为准则 ...

腫瘍微小環境 | ロシュ・ダイアグノスティックス

... (制御性T細胞) 樹状細胞 MDSC(骨髄由来抑制細胞) 腫瘍細胞 NK細胞 線維芽細胞 周皮細胞   7+8 = 間葉起源   血 好酸球 顆粒球 肥満細胞 B細胞 マクロファージ   腫瘍微 環 ... 腫瘍微 環境 | ロシュ・ダイアグノスティックス ... 腫瘍微 環境 | ロシュ・ダイアグノスティックス ...

Mehr Ergebnisse

CUTISS AG

http://cutiss.swiss  

8952 Schlieren, Grabenstrasse 11

 +41 44 244 36 60
 info@cutiss.swiss

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

CUTISS AG

Grabenstrasse 11

8952 Schlieren

161 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter CUTISS AG

Comments on: EMA authorizes Phase 3 clinical trial for denovoSkin™

... Comments on: EMA authorizes Phase 3 clinical trial for denovoSkin™ Comments on: EMA authorizes ... Comments on: EMA authorizes Phase 3 clinical trial for denovoSkin™ ... https://cutiss.swiss/ ema-authorizes-phase-3-clinical-trial-for-denovoskin/feed/ ... Comments on: EMA authorizes Phase 3 clinical trial for denovoSkin™ ...

EMA authorizes Phase 3 clinical trial for denovoSkin™ – CUTISS

... EMA authorizes Phase 3 clinical trial for denovoSkin™ – CUTISS ... https://cutiss.swiss/ ema-authorizes-phase-3-clinical-trial-for-denovoskin/ ... EMA authorizes Phase 3 clinical trial for denovoSkin™ – CUTISS ...

Mehr Ergebnisse

ETH Entrepreneurship

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18


 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

ETH Entrepreneurship

Wagistrasse 18

8952 Schlieren

1880 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter ETH Entrepreneurship

Imprint – Wolfgang Pauli Lectures | ETH Zurich

... Imprint – Wolfgang Pauli Lectures | ETH Zurich ... https:// pauli-lectures.ethz.ch/footer/imprint.html ... Imprint – Wolfgang Pauli Lectures | ETH Zurich ...

Archive – Wolfgang Pauli Lectures | ETH Zurich

... , Riemann-Roch und Anwendungen Princeton University, Princeton, NJ, USA The Pauli principle and the ... Archive – Wolfgang Pauli Lectures | ETH Zurich ... https:// pauli-lectures.ethz.ch/archive.html ... Archive – Wolfgang Pauli Lectures | ETH Zurich ...

Mehr Ergebnisse

Bio-Technopark Schlieren-Zürich

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

Bio-Technopark Schlieren-Zürich

Wagistrasse 23

8952 Schlieren

8 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter Bio-Technopark Schlieren-Zürich

EMA authorizes Phase 3 clinical trial for denovoSkin™ › BIO-TECHNOP...

... News EMA authorizes Phase 3 clinical trial for denovoSkin™ CUTISS has received authorization from ... the European Medicines Agency ( EMA) to commence the Phase 3 clinical trial for our lead product ... EMA authorizes Phase 3 clinical trial for denovoSkin™ › BIO-TECHNOPARK® Schlieren-Zürich ... https://www.bio-technopark.ch/en/news-en/ ema-authorizes-phase-3-clinical-trial-for-denovoskin/ ... EMA authorizes Phase 3 clinical trial for denovoSkin™ › BIO-TECHNOPARK® Schlieren-Zürich ...

Molecular Partners Provides Regulatory Update of European and Japan...

... application filings with both the European Medicines Agency ( EMA) and the Japanese Regulatory Agency (PMDA ... Partners of their intent to withdraw application filings with both the European Medicines Agency ( EMA) and ...

Mehr Ergebnisse

University of Zurich

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

University of Zurich

Wagistrasse 12

8952 Schlieren

738 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter University of Zurich

Transgender ist ein tiefgreifendes Gefühl / Gesprächsrunde mit Dagm...

... Meyer, Katrin . Transgender ist ein tiefgreifendes Gefühl / Gesprächsrunde mit Dagmar Pauli. In ... Transgender ist ein tiefgreifendes Gefühl / Gesprächsrunde mit Dagmar Pauli - Zurich Open ... Transgender ist ein tiefgreifendes Gefühl / Gesprächsrunde mit Dagmar Pauli - Zurich Open ... Transgender ist ein tiefgreifendes Gefühl / Gesprächsrunde mit Dagmar Pauli - Zurich Open ...

Film review: "Iraqi Odyssey" (Samir, IQ/CH/DE/AE 2015) - Zurich Ope...

... Mäder, Marie-Therese (2016). Film review: "Iraqi Odyssey" (Samir, IQ/CH/DE/ AE 2015). Journal for ... Film review: "Iraqi Odyssey" (Samir, IQ/CH/DE/ AE 2015) - Zurich Open Repository and Archive ... Film review: "Iraqi Odyssey" (Samir, IQ/CH/DE/ AE 2015) - Zurich Open Repository and Archive Header ... Film review: "Iraqi Odyssey" (Samir, IQ/CH/DE/ AE 2015) - Zurich Open Repository and Archive ...

Mehr Ergebnisse

Somagenetix

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

Somagenetix

Wagistrasse 23

8952 Schlieren

912 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter Somagenetix

Thermal preferences of subtropical Aedes aegypti and temperate Ae. ...

... temperate Ae. japonicus mosquitoes were investigated in a temperature gradient set-up consisting of a ... subtropical Aedes aegypti and temperate Ae. japonicus mosquitoes were investigated in a temperature gradient ... Thermal preferences of subtropical Aedes aegypti and temperate Ae. japonicus mosquitoes - Zurich ... Thermal preferences of subtropical Aedes aegypti and temperate Ae. japonicus mosquitoes - Zurich ... Thermal preferences of subtropical Aedes aegypti and temperate Ae. japonicus mosquitoes - Zurich ...

Mehr Ergebnisse

Topadur Pharma AG

http://www.topadur.com/  

8952 Schlieren, Grabenstrasse 11a

A team dedicated to develop innovative speciality medication for the treatment of severe wound-healing problems enabling significant improvements of patients quality of life. TOPADUR’s lead R&D programs are local active, highly potent, dual mode of action drugs. TOPADUR’s unique development candidates #3;work on validated drug targets resulting in higher than average clinical success chances.

Topadur Pharma AG

Grabenstrasse 11a

8952 Schlieren

3 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter Topadur Pharma AG

Topadur Pharma

... 15.10.21 EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers Zurich ... Medicines Agency ( EMA) has granted Orphan Drug Designation (ODD) to TOP-N53, the company’s lead product, for ... https://www.topadur.com/news/ ema-grants-top-n53-orphan-drug-designation-for-the-treatment-of ... EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers Zurich-Schlieren ...

Topadur Pharma

... , CEO of TOPADUR PHARMA AG. Press Release EMA grants TOP-N53 Orphan Drug Designation for the Treatment ... of Digital Ulcers EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in ... more 15.10.21 Press Release EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital ... Ulcers EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic ...

Mehr Ergebnisse

Neurimmune Therapeutics AG

http://www.neurimmune.com  

8952 Schlieren, Wagistrasse 18

 +41 44 755 46 46
 info@neurimmune.com

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.

Neurimmune Therapeutics AG

Wagistrasse 18

8952 Schlieren

4 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter Neurimmune Therapeutics AG

Neurimmune - 01.06.2016: Aducanumab accepted into EMA's PRIME Program

... accepted into the European Medicines Agency's ( EMA) PRiority MEdicines (PRIME) program. PRIME aims to bring ... into the European Medicines Agency's ( EMA) PRiority MEdicines (PRIME) program. PRIME aims to bring ...

Neurimmune - 01.06.2016: Aducanumab accepted into EMA's PRIME Program

... accepted into the European Medicines Agency's ( EMA) PRiority MEdicines (PRIME) program. PRIME aims to bring ... Disease (AD), was accepted into the European Medicines Agency's ( EMA) PRiority MEdicines (PRIME) program ...

Mehr Ergebnisse

University Hospital Zurich​, Research and Education Office

https://www.usz.ch/forschung/Seiten/default.aspx  

8091 Zürich, Rämistrasse 100

The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.

University Hospital Zurich​, Research and Education Office

Rämistrasse 100

8091 Zürich

87 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter University Hospital Zurich​, Research and Education Office

... evaluations of safety and effectiveness and for other issues, such as treatment com- pliance and disease risk ... » minimum requirements for registries (see the re com- mendations issued by the ANQ, FMH, H+, SAMS, and ... evaluations of safety and effectiveness and for other issues, such as treatment com- pliance and disease risk ... » minimum requirements for registries (see the re com- mendations issued by the ANQ, FMH, H+, SAMS, and ...

... least one-third of the cases, AE is diagnosed incidentally during a medical workup for abnormal ... laboratory tests or symptoms and signs. AE symptoms and prognosis are primarily dependent on location and ... least one-third of the cases, AE is diagnosed incidentally during a medical workup for abnormal ... laboratory tests or symptoms and signs. AE symptoms and prognosis are primarily dependent on location and ...

Mehr Ergebnisse

CSL Vifor

https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor  

8952 Schlieren, Zürcherstrasse 39D

 +41 58 851 80 00

Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.

CSL Vifor

Zürcherstrasse 39D

8952 Schlieren

12 Ergebnisse für "jdj AE诈骗集团老板郭哲敏 小明 pauli 曝光网址ù ema ø'd com Ae骗子平台 郭哲敏诈骗全东南亚越南站长cZ" unter CSL Vifor

News Releases | CSL

... Application for ARCT-154 Vaccine to Prevent COVID-19 EMA application supported by Phase 3 primary vaccination ... , announced today that the European Medicines Agency ( EMA) has validated the marketing authorization ... Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19 EMA application ... influenza vaccine providers in the world, announced today that the European Medicines Agency ( EMA) has ...

News Releases | CSL

... Agency ( EMA). CSL is also investigating garadacimab for other indications, beyond HAE, where FXIIa ... (FDA) and the European Medicines Agency ( EMA). CSL is also investigating garadacimab for other ...

Mehr Ergebnisse

Mehr Firmen

Nach oben